Case series: Brolucizumab efficacy and safety in treating neovascular age‐related macular degeneration

Case series: Brolucizumab efficacy and safety in treating neovascular age‐related macular degeneration

Saved in:

Bibliographic Details
Main Authors:	Linling Cheng, Charlotte L. Zhang, Cheryl C. Lai, Ning Sun, Hiuwa Hang
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Series:	MedComm – Future Medicine
Online Access:	https://doi.org/10.1002/mef2.70010
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2023-01-01)

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration
by: Shigeru Honda, et al.
Published: (2025-02-01)

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
by: Asim K Ghosh, et al.
Published: (2025-06-01)

Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab
by: Settimio Rossi, et al.
Published: (2025-01-01)

Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study
by: Deependra Vikram Singh, et al.
Published: (2024-12-01)

Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital
by: Lorenzo Fabozzi, et al.
Published: (2024-11-01)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
by: Hang A, et al.
Published: (2024-12-01)

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study
by: Masayuki Ohnaka, et al.
Published: (2025-05-01)

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration
by: Federico Beretta, et al.
Published: (2025-04-01)

Dynamics of Inflammatory Factors in Aqueous Humor During Brolucizumab Treatment for Age-Related Macular Degenerations: A Case Series
by: Masaki Asakage, et al.
Published: (2025-02-01)

Photodynamic therapy for neovascular age-related macular degeneration
by: Richard P.L. Wormald, MA, MB, BCh, MSc, FRCS, FRCOphth, et al.
Published: (2005-06-01)

Intravitreal bevacizumab for neovascular age-related macular degeneration
by: Junn R. Pajarillo, MD, et al.
Published: (2009-12-01)

OCT predictors of retinal atrophy in neovascular age-related macular degeneration treated with aflibercept
by: Oscar M. Gagliardi, et al.
Published: (2025-04-01)

Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
by: Francisco Rodríguez, et al.
Published: (2024-05-01)

Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
by: Ryo Mukai, et al.
Published: (2021-01-01)

Evaluation of the efficacy of surgical treatment of cataracts in patients with neovascular age-related macular degeneration
by: A. Zh. Fursova, et al.
Published: (2024-12-01)

Early detection of choroidal neovascularization in age related macular degeneration
by: Tural Galbinur
Published: (2014-07-01)

Retinal sensitivity above macular neovascularization under anti-VEGF therapy in exudative neovascular age-related macular degeneration
by: Laurenz Pauleikhoff, et al.
Published: (2025-03-01)

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

The Relationship between Neovascular Age-Related Macular Degeneration and Erectile Dysfunction
by: Harun Çakmak, et al.
Published: (2013-01-01)

Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
by: F. A. Bakhritdinova, et al.
Published: (2018-10-01)

Research progress in molecular omics of neovascular age-related macular degeneration
by: ZHUANG Xuenan, et al.
Published: (2025-02-01)

Potential of autophagy in subretinal fibrosis in neovascular age-related macular degeneration
by: Janusz Blasiak, et al.
Published: (2025-04-01)

Comparison of OCT Angiography Parameters after Administration of Intravitreal Brolucizumab versus Ranibizumab in Exudative Age-related Macular Degeneration
by: Sanjitha Vilma Moses, et al.
Published: (2024-12-01)

Five-year Outcome of Aflibercept Administration with “Treat and Extend” for Neovascular Age-Related Macular Degeneration
by: Wada I, et al.
Published: (2025-03-01)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)

Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment
by: L. A. Golota, et al.
Published: (2025-03-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

Clinical Characteristics of Neovascular Age-Related Macular Degeneration without Typical Drusen
by: Hiroyuki Kamao, et al.
Published: (2021-01-01)

Metformin inhibits pathological retinal neovascularization but promotes retinal fibrosis in experimental neovascular age-related macular degeneration
by: Xin Wang, et al.
Published: (2025-03-01)

Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema
by: Sanjay Kumar Mishra, et al.
Published: (2025-01-01)

Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy
by: Yousif Subhi, et al.
Published: (2017-01-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Short-term natural history of macular neovascularization in nonexudative age-related macular degeneration using multimodal imaging
by: Anna-Maria Haas, et al.
Published: (2025-07-01)

Risk Factor of Neovascular Agerelated Macular Degeneration Progression after Cataract Surgery
by: V. G. Likhvantseva, et al.
Published: (2024-04-01)

Clinical, functional and aberrometric parallels in the treatment of the neovascular form of age-related macular degeneration
by: M. M. Magomedova, et al.
Published: (2024-07-01)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
by: Zeynep Alkin, et al.
Published: (2013-01-01)

Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
by: Kai Fang, et al.
Published: (2013-01-01)

Quantitative characterization of types 1 and 2 macular neovascularization in neovascular age-related macular degeneration with intravitreal conbercept: an analysis utilizing optical coherence tomography angiography
by: Yan-Mei Shi, et al.
Published: (2025-08-01)

Efficacy and Safety of Nutraceutical Support in Age-Related Macular Degeneration Patients
by: S. V. Yanchenko, et al.
Published: (2023-01-01)